CASI Pharmaceuticals, Inc.
CASI
$0.94
$0.010.88%
NASDAQ
| 09/30/2025 | 03/31/2025 | 12/31/2024 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.54% | 83.04% | 94.30% | 94.30% | -11.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.54% | 83.04% | 94.30% | 94.30% | -11.82% |
| Cost of Revenue | -36.79% | 63.51% | 259.79% | 259.79% | 2.74% |
| Gross Profit | -82.55% | 100.39% | -20.47% | -20.47% | -22.06% |
| SG&A Expenses | -10.10% | 39.44% | 3.01% | 3.01% | 31.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 99.96% | 99.96% | -- |
| Total Operating Expenses | -16.12% | 30.45% | 120.90% | 120.90% | 12.72% |
| Operating Income | -26.70% | -11.00% | -159.27% | -159.27% | -54.06% |
| Income Before Tax | -29.64% | -12.83% | -143.85% | -143.85% | -87.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.64% | -12.83% | -143.89% | -143.89% | -87.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.64% | -12.83% | -137.32% | -137.32% | -81.12% |
| EBIT | -26.70% | -11.00% | -159.27% | -159.27% | -54.06% |
| EBITDA | -35.13% | -16.50% | -207.36% | -207.36% | -54.01% |
| EPS Basic | -23.54% | 2.54% | -65.19% | -65.19% | -58.41% |
| Normalized Basic EPS | -7.31% | 3.25% | -87.11% | -87.11% | -77.81% |
| EPS Diluted | -23.54% | 2.54% | -64.58% | -64.58% | -58.41% |
| Normalized Diluted EPS | -7.31% | 3.25% | -87.11% | -87.11% | -77.81% |
| Average Basic Shares Outstanding | 4.94% | 15.77% | 43.16% | 43.16% | 14.32% |
| Average Diluted Shares Outstanding | 4.94% | 15.77% | 43.16% | 43.16% | 14.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |